Physician profile
Robert Hemphill
NPI 1073608774
$411.75
in general payments reported to CMS, 2019-2025
14 companies · $19.66 in 2025
The $19.66 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $188 · 2023: $18.33 · 2024: $186 · 2025: $19.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $61.36 | 2024 | Rybrevant |
| Alexion Pharmaceuticals, INC. | $54.00 | 2022-2025 | Ultomiris |
| Array Biopharma INC | $49.10 | 2022-2023 | Mektovi, Lorbrena, Braftovi |
| Takeda Pharmaceuticals U.S.A., INC. | $36.06 | 2022 | |
| G1 Therapeutics, INC. | $29.85 | 2022 | |
| Pfizer INC. | $23.19 | 2024 | |
| Incyte Corporation | $23.12 | 2024 | Monjuvi |
| Ipsen Biopharmaceuticals, INC | $21.69 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.81 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.75 | 2022 | |
| Servier Pharmaceuticals LLC | $18.94 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.74 | 2024 | |
| Adc Therapeutics America, INC. | $18.41 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hemphill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.